Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The treatment of hepatocellular carcinoma has shifted significantly from the era of local therapy to the era of drug therapy, partly because of changes in background factors. Drug therapy for hepatocellular carcinoma has made rapid progress in recent years. We have moved from an era where sorafenib monotherapy was used to prolong survival, to an era of sequential therapy with multiple tyrosine kinase inhibitors, and further improvements in patient prognosis have been achieved with the introduction of immunotherapy com-bining atezolizumab and bevacizumab. The availability of highly effective drugs has expanded the range of diseases treatable by drug therapy. Additionally, instead of ini-tiating drug therapy at advanced stages, combining it with local therapies such as transarterial chemoembolization at an earlier stage with the aim of achieving a cure has become possible, improving treatment outcomes further. Currently, the number of regimens requiring consideration, involving combinations of multiple drugs and local therapies, has increased, leading to various trials being conducted. Additionally, cases of hepatocellular carcinoma that were previously unresectable have become resectable after drug therapy, necessitating the establishment of a resectability classification system. This review summarises the current evidence for drug therapy of hepatocellular carcinoma and discusses future treatment strategies, treatment combinations, and prospects.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
- Date Crossref
- 04/06/2025
- Éditeur
- MDPI AG
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Hospital Organization Kyushu Cancer Center pays non établi dans la noticeÉtablissement de santé
-
National Kyushu Medical Center pays non établi dans la noticeÉtablissement de santé
-
Kyushu University pays non établi dans la noticeUniversité ou école supérieure
-
Department of Hepato-Biliary-Pancreatology NHO Kyushu Cancer Center pays non établi dans la noticeInstitution
-
National Hospital Organization Kyushu Medical Center Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Graduate School of Medical Sciences Department of Medicine and Bioregulatory Science pays non établi dans la noticeUniversité ou école supérieure
National Hospital Organization Kyushu Cancer Center, National Kyushu Medical Center et Kyushu University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.